Safety of dupilumab in atopic patients during COVID-19 outbreak-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety of dupilumab in atopic patients during COVID-19 outbreak

Published:2020-06-19 Issue: Volume: Page:1-2
ISSN:0954-6634
Container-title:Journal of Dermatological Treatment
language:en
Short-container-title:Journal of Dermatological Treatment

Author:

Napolitano Maddalena¹,Patruno Cataldo²,Ruggiero Angelo³,Nocerino Mariateresa³,Fabbrocini Gabriella³

Affiliation:

1. Department of Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy

2. Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, Italy

3. Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy

Publisher

Informa UK Limited

Subject

Dermatology

Link

https://www.tandfonline.com/doi/pdf/10.1080/09546634.2020.1771257

Reference11 articles.

1. Face the COVID‐19 emergency: measures applied in an Italian Dermatologic Clinic

2. Biologic therapy for psoriasis during the covid-19 outbreak is not a choice

3. Biologics for psoriasis patients in the COVID-19 era: more evidence, less fears

4. No evidence of increased risk for Coronavirus Disease 2019 (COVID‐19) in patients treated with Dupilumab for atopic dermatitis in a high‐epidemic area – Bergamo, Lombardy, Italy

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advancements in acne detection: application of the CenterNet network in smart dermatology;Frontiers in Medicine;2024-03-25

2. Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review;Journal of Allergy and Clinical Immunology: Global;2024-02

3. T helper cell subsets: diversification of the field;European Journal of Immunology;2023-03-03

4. Advanced Squamous Cell Carcinoma Developed on Chronic Hidradenitis Suppurativa, Successfully Treated with Cemiplimab: A Case Report;Case Reports in Dermatology;2023-02-14

5. Dupilumab for Atopic Dermatitis—From Clinical Trials to Molecular and Cellular Mechanisms;Dermatitis®;2023-02-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3